Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
Ildiko Lingvay, Ofri Mosenzon, Katelyn Brown, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Randomized Trial of Effect of Bariatric Surgery on Blood Pressure After 5 Years
Carlos A. Schiavon, Alexandre Biasi Cavalcanti, Juliana D. Oliveira, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 6, pp. 637-648
Closed Access | Times Cited: 27
Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes
Min‐Hsiang Chuang, Jui‐Yi Chen, Hsien‐Yi Wang, et al.
JAMA Network Open (2024) Vol. 7, Iss. 8, pp. e2427258-e2427258
Open Access | Times Cited: 23
Characteristics and Dosing Patterns of Tirzepatide Users with Type 2 Diabetes in the United States
Reema Mody, Karishma Desai, Chia‐Chen Teng, et al.
Diabetes Therapy (2025)
Open Access | Times Cited: 2
Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future
Irene Caruso, Francesco Giorgino
Endocrine (2024) Vol. 84, Iss. 3, pp. 822-835
Open Access | Times Cited: 14
Beyond glycemia: Comparing tirzepatide to GLP-1 analogues
John Andraos, Harleen Muhar, Shawn Smith
Reviews in Endocrine and Metabolic Disorders (2023) Vol. 24, Iss. 6, pp. 1089-1101
Open Access | Times Cited: 18
Weight Loss Therapies and Hypertension Benefits
Vasiliki Katsi, Eleni Manta, Christos Fragoulis, et al.
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2293-2293
Open Access | Times Cited: 5
Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS‐AP‐Combo
Jianhua Ma, Ming Liu, Rui Wang, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 4, pp. 1454-1463
Open Access | Times Cited: 4
Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future
Ying Jie Chee, Rinkoo Dalan
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1386-1386
Open Access | Times Cited: 4
Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J‐mono trial
Hanaka Mimura, Tomonori Oura, Rina Chin, et al.
Journal of Diabetes Investigation (2025)
Open Access
Antihypertensive Medications in Patients With Weight Loss
Farrin A. Manian
JAMA Internal Medicine (2025)
Closed Access
Blood pressure lowering efficacy of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists compared to glucagon-like peptide-1 (GLP-1) receptor agonists
G. Grenet, A. Gougeon, Douglas M Salzwedel, et al.
Cochrane library (2025) Vol. 2025, Iss. 4
Closed Access
Managing Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment
Grzegorz Rudzki, Kinga Knop-Chodyła, Zuzanna Piasecka, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 8, pp. 987-987
Open Access | Times Cited: 3
Perspectives on weight control in diabetes – Tirzepatide
Tamás Várkonyi, Anikó Pósa, Noémi Pávó, et al.
Diabetes Research and Clinical Practice (2023) Vol. 202, pp. 110770-110770
Open Access | Times Cited: 8
The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study
Jamy D. Ard, Ian J. Neeland, Amy E. Rothberg, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 3, pp. 950-960
Open Access | Times Cited: 8
Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review
Alexandros L. Liarakos, Chrysi Koliaki
Biomedicines (2023) Vol. 11, Iss. 7, pp. 1875-1875
Open Access | Times Cited: 7
Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program
Stephen J. Nicholls, Santiago Tofé, Carel W. le Roux, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide
Shweta Urva, Joshua A. Levine, Karen Schneck, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 4, pp. 567-574
Open Access | Times Cited: 2
Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program
Philip Zeitler, Rodolfo J. Galindo, Melanie J. Davies, et al.
Diabetes Care (2024) Vol. 47, Iss. 6, pp. 1056-1064
Open Access | Times Cited: 2
Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials
Moein Ala, Razieh Mohammad Jafari, Ahmad Reza Dehpour, et al.
International Journal of Obesity (2024)
Closed Access | Times Cited: 2
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data
Ronald Goldenberg, Hwee Teoh, Subodh Verma
Current Opinion in Cardiology (2023) Vol. 38, Iss. 6, pp. 539-545
Closed Access | Times Cited: 6
Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases
Sulayman A. Lyons, Jacqueline L. Beaudry
Endocrinology (2023) Vol. 164, Iss. 11
Open Access | Times Cited: 6
OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes
Simone Anna Melander, Ashref Kayed, Kim Vietz Andreassen, et al.
European Journal of Pharmacology (2023) Vol. 962, pp. 176215-176215
Open Access | Times Cited: 6
Call to action for drug interactions between tirzepatide and heart failure guideline-directed medical therapy
Kazuhiko Kido, Brittany Carey, Marco Caccamo, et al.
Journal of the American Pharmacists Association (2023) Vol. 64, Iss. 1, pp. 169-173
Open Access | Times Cited: 5
Tirzepatide: unveiling a New Dawn in Dual-Targeted diabetes and obesity management
Syed Arman Rabbani, Mohamed El‐Tanani, Ismail Matalka, et al.
Expert Review of Endocrinology & Metabolism (2024) Vol. 19, Iss. 6, pp. 487-505
Closed Access | Times Cited: 1
Cardiovascular and kidney benefits of SGLT-2is and GLP-1RAs according to baseline blood pressure in type 2 diabetes: a systematic meta-analysis of cardiovascular outcome trials
Setor K. Kunutsor, Samuel Seidu, Richard S. Dey, et al.
Scandinavian Cardiovascular Journal (2024) Vol. 58, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top